|
Patent landscape, scope, and claims summary: |
United States Patent 9,695,226: Claims, Validity Risks, and U.S. Patent Estate Map
No complete claim text was provided for U.S. Patent 9,695,226 (“ ’226”). Without the asserted claims (independent and dependent claim language), a complete and accurate claim-by-claim infringement, validity, and landscape analysis cannot be produced under the required standard.
What is U.S. Patent 9,695,226’s claim scope and what would be infringed?
Featured snippet answer: Cannot be determined because the claim language was not provided. Claim scope analysis requires the exact wording of at least all independent claims and representative dependent claims (elements, limitations, ranges, compositions, method steps, and definitions).
How do independent claims define the “invention” in the ’226 patent?
- Not analyzable without claim text. Independent claims typically drive:
- infringement element mapping,
- anticipation/obviousness comparisons,
- design-around search,
- potential claim construction positions in litigation.
Which dependent claims narrow scope (or create separate infringement hooks)?
- Not analyzable without dependent claim language.
What claim limitations are likely construed narrowly vs broadly?
- Not analyzable without the limitations and their defined terms.
Which prior art references could anticipate or render U.S. Patent 9,695,226 obvious?
Featured snippet answer: Cannot be determined. Novelty and non-obviousness analysis depends on the concrete limitations in the ’226 claims.
What evidence typically defeats novelty in this claim structure?
- Requires claim-by-claim mapping to:
- single-reference anticipation,
- multi-reference obviousness combinations,
- printed publication dates and enablement.
What patent family members and prosecution history could control interpretation?
- Requires access to:
- file wrapper,
- continuations,
- amendments distinguishing prior art,
- disclaimer language.
What non-patent literature (NPL) usually matters for this type of claim?
- Requires claim topic classification (composition, method, device, system, process, dosing regimen).
When does U.S. Patent 9,695,226 expire and what exclusivity layers matter in the U.S.?
Featured snippet answer: Cannot be determined from the information provided. Expiration requires the patent’s key dates:
- earliest effective filing date (for 35 USC 154 calculation),
- any PTA (patent term adjustment),
- any terminal disclaimer,
- whether it is part of a family with earlier filings that control the legal term.
What is the likely legal expiration date under 35 USC 154?
- Not analyzable without priority and prosecution timing.
How does PTA and terminal disclaimer change enforceability?
- Not analyzable without USPTO record details.
Does any regulatory exclusivity extend market protection beyond the patent term?
- Not analyzable without knowing the drug/biologic context and FDA exclusivity status.
Is U.S. Patent 9,695,226 in the Orange Book and what does that imply for generic entry risk?
Featured snippet answer: Cannot be determined. Orange Book listing depends on:
- the marketed NDA/ANDA product,
- the listed patent numbers and submission type (drug substance, drug product, method of use).
What is the Orange Book status of the ’226 patent (NDA/ANDA tie)?
- Not analyzable without the associated NDA/route/product.
If listed, what patent submission type is it (1/2/3)?
- Not analyzable without Orange Book entry details.
What would be the likely FDA litigation trigger: paragraph IV vs 30-month stay?
- Requires whether the ’226 is listed and which applicant challenged.
What generic or biosimilar challenges does U.S. Patent 9,695,226 face (Paragraph IV and litigation)?
Featured snippet answer: Cannot be determined. This requires:
- Paragraph IV notices filed,
- district court dockets,
- parties and asserted counts.
Which companies are challenging the ’226 patent?
- Not analyzable without docket and notice data.
What outcomes or settlements affect practical enforceability?
- Requires:
- settlement agreements,
- consent judgments,
- stipulations of dismissal,
- agreed launch dates.
What is the status of any IPR/CBM challenges against the ’226?
- Requires PTAB docket data.
How strong is the patent estate around U.S. Patent 9,695,226 (continuations, family breadth, claim redundancy)?
Featured snippet answer: Cannot be determined. Estate strength depends on:
- related family members,
- continuation claims,
- breadth of claim types across the family,
- prosecution history and art coverage.
Does the family include composition, formulation, or method-of-use continuations?
- Not analyzable without knowing the invention and family set.
Are there multiple independent claim “tracks” that reduce design-around risk?
- Not analyzable without claim set and family structure.
How many enforceable claims remain after typical claim construction and validity attacks?
- Not analyzable without claim text and historical validity posture.
What formulations or methods are protected by the ’226 patent?
Featured snippet answer: Cannot be determined. Protection depends on:
- dosage form and formulation claim language (active, excipients, particle size, crystalline form, polymorph, solvate, co-crystal),
- method-of-use or dosing regimen limitations,
- process parameters and manufacturing steps.
Is the ’226 patent focused on drug substance, drug product, or method-of-use?
- Not analyzable without claim text.
Are there specific parameters (ranges, temperature/time, pH, particle size, crystallinity)?
- Not analyzable without claim language.
Do claims cover combination regimens or specific patient populations?
- Not analyzable without claim language.
How does U.S. Patent 9,695,226 compare to nearby patents in the same technological space?
Featured snippet answer: Cannot be determined. Comparison requires:
- identification of the drug/product and technological class,
- mapping of overlapping limitations with close prior art and neighboring patents.
What are the most relevant “closest” patents to consider for freedom-to-operate (FTO)?
- Not analyzable without topic.
Are there overlapping claims that create cumulative injunction risk?
- Not analyzable without knowing claim scope.
Where do competitors likely design around the ’226 limitations?
- Not analyzable without claim language.
Key Takeaways
- A comprehensive, critical analysis of U.S. Patent 9,695,226 cannot be completed because the claim text was not provided.
- Patent expiration, Orange Book status, litigation risk, and enforceability all require identification of claim scope, associated product context, and legal dates, none of which can be reliably derived from the provided input.
FAQs
-
What does “US 9,695,226” protect in the U.S. specifically?
Cannot be determined without the actual claim language.
-
Can a generic company launch “at-risk” while US 9,695,226 is still enforceable?
Cannot be determined without Orange Book listing and litigation posture.
-
What prior art types are most likely to challenge a drug-related composition patent like US 9,695,226?
Depends on whether the claims are composition, formulation, or method-of-use.
-
Does US 9,695,226 likely face PTAB IPR challenges, and what grounds are typical?
Cannot be determined without knowing the patent family and claim structure.
-
How do terminal disclaimers and PTA affect enforcement timing for US 9,695,226?
Requires the patent’s priority date and USPTO timing records.
References
(None provided because no sources were cited and no claim text or patent-context details were supplied.)
More… ↓
⤷ Start Trial
|
